Skip to main content Accessibility Statement

Investors

At Tactile Medical, a fundamental value is to earn a fair profit and return value for our shareholders


--

Minimum 15 minutes delayed. Source:

Upcoming Events


More events are coming soon.

Recent News


  • Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform

    Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema MINNEAPOLIS , Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic

    Read more
  • Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy

    Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints MINNEAPOLIS , Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a

    Read more
  • Tactile Medical Receives PDAC Approval for Nimbl™ Lymphedema Platform

    Next-Generation System Significantly Reduces Device Size and Weight and Enables Integration with Kylee™ Digital App MINNEAPOLIS , Sept. 16, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies

    Read more